Clinical significance of the t(14; 18) and BCL2 overexpression in follicular large cell lymphoma

Dennis D. Weisenburger, Randy D. Gascoyne, Philip Jay Bierman, Tamara Shenkier, Douglas E. Horsman, James C. Lynch, Wing C. Chan, Timothy Charles Greiner, Joseph M. Connors, Julie Marie Vose, James Olen Armitage, Warren G. Sanger

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Follicular large cell lymphoma (FLCL) is an aggressive disease that responds to anthracycline-containing chemotherapy much like diffuse large B-cell lymphoma (DLBCL). Since the t(14;18) and/or bcl2 protein expression are less common in FLCL than in its low-grade counterparts, we sought to determine whether these features were predictive of survival as in DLBCL. We studied 50 patients with FLCL who were treated with curative intent. The t(14;18) was found by cytogenetic analysis in 56% of the patients and bcl2 protein was expressed by the tumor cells in 73%, but neither was predictive of survival. However, abnormalities of chromosome 17p and the presence of trisomy 21 were adverse predictors of survival, as were a number of clinical features. We conclude that neither the absence of the t(14;18) nor the lack of bcl2 expression explain the good response of a subset of patients with FLCL to curative therapy.

Original languageEnglish (US)
Pages (from-to)513-523
Number of pages11
JournalLeukemia and Lymphoma
Volume36
Issue number5-6
DOIs
StatePublished - Jan 1 2000

Fingerprint

Follicular Lymphoma
Lymphoma, Large B-Cell, Diffuse
Survival
Cytogenetic Analysis
Anthracyclines
Down Syndrome
Chromosome Aberrations
Proteins
Drug Therapy
Neoplasms
Therapeutics

Keywords

  • BCL2
  • Cytogenetics
  • Follicular large cell lymphoma
  • Follicular lymphoma
  • Non-Hodgkin's lymphoma
  • T(14;18)

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Weisenburger, D. D., Gascoyne, R. D., Bierman, P. J., Shenkier, T., Horsman, D. E., Lynch, J. C., ... Sanger, W. G. (2000). Clinical significance of the t(14; 18) and BCL2 overexpression in follicular large cell lymphoma. Leukemia and Lymphoma, 36(5-6), 513-523. https://doi.org/10.3109/10428190009148399

Clinical significance of the t(14; 18) and BCL2 overexpression in follicular large cell lymphoma. / Weisenburger, Dennis D.; Gascoyne, Randy D.; Bierman, Philip Jay; Shenkier, Tamara; Horsman, Douglas E.; Lynch, James C.; Chan, Wing C.; Greiner, Timothy Charles; Connors, Joseph M.; Vose, Julie Marie; Armitage, James Olen; Sanger, Warren G.

In: Leukemia and Lymphoma, Vol. 36, No. 5-6, 01.01.2000, p. 513-523.

Research output: Contribution to journalArticle

Weisenburger, DD, Gascoyne, RD, Bierman, PJ, Shenkier, T, Horsman, DE, Lynch, JC, Chan, WC, Greiner, TC, Connors, JM, Vose, JM, Armitage, JO & Sanger, WG 2000, 'Clinical significance of the t(14; 18) and BCL2 overexpression in follicular large cell lymphoma', Leukemia and Lymphoma, vol. 36, no. 5-6, pp. 513-523. https://doi.org/10.3109/10428190009148399
Weisenburger, Dennis D. ; Gascoyne, Randy D. ; Bierman, Philip Jay ; Shenkier, Tamara ; Horsman, Douglas E. ; Lynch, James C. ; Chan, Wing C. ; Greiner, Timothy Charles ; Connors, Joseph M. ; Vose, Julie Marie ; Armitage, James Olen ; Sanger, Warren G. / Clinical significance of the t(14; 18) and BCL2 overexpression in follicular large cell lymphoma. In: Leukemia and Lymphoma. 2000 ; Vol. 36, No. 5-6. pp. 513-523.
@article{9b0679dba9fd48ae8d49dece9ce59819,
title = "Clinical significance of the t(14; 18) and BCL2 overexpression in follicular large cell lymphoma",
abstract = "Follicular large cell lymphoma (FLCL) is an aggressive disease that responds to anthracycline-containing chemotherapy much like diffuse large B-cell lymphoma (DLBCL). Since the t(14;18) and/or bcl2 protein expression are less common in FLCL than in its low-grade counterparts, we sought to determine whether these features were predictive of survival as in DLBCL. We studied 50 patients with FLCL who were treated with curative intent. The t(14;18) was found by cytogenetic analysis in 56{\%} of the patients and bcl2 protein was expressed by the tumor cells in 73{\%}, but neither was predictive of survival. However, abnormalities of chromosome 17p and the presence of trisomy 21 were adverse predictors of survival, as were a number of clinical features. We conclude that neither the absence of the t(14;18) nor the lack of bcl2 expression explain the good response of a subset of patients with FLCL to curative therapy.",
keywords = "BCL2, Cytogenetics, Follicular large cell lymphoma, Follicular lymphoma, Non-Hodgkin's lymphoma, T(14;18)",
author = "Weisenburger, {Dennis D.} and Gascoyne, {Randy D.} and Bierman, {Philip Jay} and Tamara Shenkier and Horsman, {Douglas E.} and Lynch, {James C.} and Chan, {Wing C.} and Greiner, {Timothy Charles} and Connors, {Joseph M.} and Vose, {Julie Marie} and Armitage, {James Olen} and Sanger, {Warren G.}",
year = "2000",
month = "1",
day = "1",
doi = "10.3109/10428190009148399",
language = "English (US)",
volume = "36",
pages = "513--523",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "5-6",

}

TY - JOUR

T1 - Clinical significance of the t(14; 18) and BCL2 overexpression in follicular large cell lymphoma

AU - Weisenburger, Dennis D.

AU - Gascoyne, Randy D.

AU - Bierman, Philip Jay

AU - Shenkier, Tamara

AU - Horsman, Douglas E.

AU - Lynch, James C.

AU - Chan, Wing C.

AU - Greiner, Timothy Charles

AU - Connors, Joseph M.

AU - Vose, Julie Marie

AU - Armitage, James Olen

AU - Sanger, Warren G.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Follicular large cell lymphoma (FLCL) is an aggressive disease that responds to anthracycline-containing chemotherapy much like diffuse large B-cell lymphoma (DLBCL). Since the t(14;18) and/or bcl2 protein expression are less common in FLCL than in its low-grade counterparts, we sought to determine whether these features were predictive of survival as in DLBCL. We studied 50 patients with FLCL who were treated with curative intent. The t(14;18) was found by cytogenetic analysis in 56% of the patients and bcl2 protein was expressed by the tumor cells in 73%, but neither was predictive of survival. However, abnormalities of chromosome 17p and the presence of trisomy 21 were adverse predictors of survival, as were a number of clinical features. We conclude that neither the absence of the t(14;18) nor the lack of bcl2 expression explain the good response of a subset of patients with FLCL to curative therapy.

AB - Follicular large cell lymphoma (FLCL) is an aggressive disease that responds to anthracycline-containing chemotherapy much like diffuse large B-cell lymphoma (DLBCL). Since the t(14;18) and/or bcl2 protein expression are less common in FLCL than in its low-grade counterparts, we sought to determine whether these features were predictive of survival as in DLBCL. We studied 50 patients with FLCL who were treated with curative intent. The t(14;18) was found by cytogenetic analysis in 56% of the patients and bcl2 protein was expressed by the tumor cells in 73%, but neither was predictive of survival. However, abnormalities of chromosome 17p and the presence of trisomy 21 were adverse predictors of survival, as were a number of clinical features. We conclude that neither the absence of the t(14;18) nor the lack of bcl2 expression explain the good response of a subset of patients with FLCL to curative therapy.

KW - BCL2

KW - Cytogenetics

KW - Follicular large cell lymphoma

KW - Follicular lymphoma

KW - Non-Hodgkin's lymphoma

KW - T(14;18)

UR - http://www.scopus.com/inward/record.url?scp=0033966462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033966462&partnerID=8YFLogxK

U2 - 10.3109/10428190009148399

DO - 10.3109/10428190009148399

M3 - Article

C2 - 10784396

AN - SCOPUS:0033966462

VL - 36

SP - 513

EP - 523

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 5-6

ER -